Loading...
Market
WHO and MPP establish H5N1 mRNA vaccine manufacturing facility in low- or middle-income country by end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
WHO official announcements, WHO website, or press releases
Story
WHO Launches Initiative Today for H5N1 mRNA Vaccine Development
Jul 29, 2024, 11:02 AM
The World Health Organization (WHO) and the Medicines Patent Pool (MPP) have launched a new initiative today to accelerate the development and accessibility of mRNA vaccines for human avian influenza (H5N1). This project aims to support manufacturers in low- and middle-income countries, ensuring they are not left behind in the vaccine distribution queue as seen in past pandemics. The initiative involves a group of emerging vaccine companies working on H5N1 mRNA vaccine candidates.
View original story
Similar markets
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Zoetis • 25%
Other • 25%
WHO • 25%
CDC • 25%
European Medicines Agency (EMA) • 25%
Other • 25%
GSK • 25%
Sanofi • 25%
CSL • 25%
None by deadline • 25%
Nigeria • 25%
Ethiopia • 25%
Bangladesh • 25%
Other • 25%
United States • 25%
China • 25%
European Union • 25%
Other • 25%
GSK • 33%
Sanofi • 33%
Seqirus • 33%
Pfizer • 25%
Johnson & Johnson • 25%
AstraZeneca • 25%
No partnership announced • 25%
